Presentation is loading. Please wait.

Presentation is loading. Please wait.

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,

Published byИсидор Дунђерски Modified over 5 years ago

Similar presentations

Presentation on theme: "Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,"— Presentation transcript:

1 Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp, MD, Hiroyuki Nagase, PhD, Frank C. Albers, PhD, Scott Doyle, DPhil (Cand), Qin Shen, PhD, Daniel J. Bratton, PhD, Necdet B. Gunsoy, PhD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 1, Pages e20 (January 2019) DOI: /j.jaci Copyright © 2018 GlaxoSmithKline Terms and Conditions

2 Fig 1 Overview of patients' baseline characteristics in the ITT populations and baseline blood eosinophil count subgroups used in the ITC. *Data for the end point of exacerbations requiring ED visits/hospitalizations were reported in the published reslizumab pooled analysis; patients had 2 or more exacerbations in the past year and GINA step 4/5 therapy. †Data for the 150 cells/μL or greater subgroup were reported in the published benralizumab pooled analysis only. ‡Because of the lack of available subgroup data for benralizumab, it was only possible to define a 450 cells/μL or greater subgroup. ICS, Inhaled corticosteroid; ITT, intent to treat. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

3 Fig 2 ITC of the rate of clinically significant exacerbations by baseline blood eosinophil count subgroups and in the ITT population. *P < .05 and **P < .01. Comparisons are presented as drug A versus drug B. Not all comparisons were possible at each blood eosinophil count threshold because of a lack of data from included studies. I2 values: 400 cells/μL or greater, 0% (MEPO vs PBO), NA (BENRA vs PBO), and 0% (RESLI vs PBO); 300 cells/μL or greater, 0% (MEPO vs PBO) and 73% (BENRA vs PBO); 150 cells/μL or greater, 0% (MEPO vs PBO) and NA (BENRA vs PBO); and unadjusted comparison, 0% (MEPO vs PBO), 73% (BENRA vs PBO), and 0% (RESLI vs PBO). BENRA, Thirty milligrams of benralizumab Q8W; MEPO, 100 mg of mepolizumab administered subcutaneously; NA, not applicable; RESLI, 3 mg/kg reslizumab. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

4 Fig 3 ITCs of the rate of exacerbations requiring ED visits/hospitalizations by baseline blood eosinophil count subgroup and in the ITT population. Comparisons are presented as drug A versus drug B. Not all comparisons were possible at each blood eosinophil count threshold because of a lack of data from included studies. I2 values: 400 cells/μL or greater, 12% (MEPO vs PBO) and NA (RESLI vs PBO); 300 cells/μL or greater, 0% (MEPO vs PBO) and 86% (BENRA vs PBO); unadjusted comparison, 0% (MEPO vs PBO), 86% (BENRA vs PBO), and 0% (RESLI vs PBO). BENRA, Thirty milligrams of benralizumab Q8W; MEPO, 100 mg of mepolizumab administered subcutaneously; NA, not applicable; PBO, placebo; RESLI, 3 mg/kg reslizumab. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

5 Fig 4 ITCs of the change from baseline in ACQ score by baseline blood eosinophil count subgroups and in the ITT population. *P < .05 and **P < .01. Comparisons are presented as drug A versus drug B. Not all comparisons were possible at each blood eosinophil count threshold because of a lack of data from included studies. I2 values: 400 cells/μL or greater, 28% (MEPO vs PBO), NA (BENRA vs PBO), and 0% (RESLI vs PBO); 300 cells/μL or greater, 60% (MEPO vs PBO) and 0% (BENRA vs PBO); 150 cells/μL or greater, 0% (MEPO vs PBO) and NA (BENRA vs PBO); unadjusted comparison, 0% (MEPO vs PBO), 0% (BENRA vs PBO), and 0% (RESLI vs PBO). BENRA, Thirty milligrams of benralizumab Q8W; MEPO, 100 mg of mepolizumab administered subcutaneously; NA, not applicable; PBO, placebo; RESLI, 3 mg/kg reslizumab. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

6 Fig 5 ITCs of the change from baseline in prebronchodilator FEV1 (in liters) by baseline blood eosinophil count subgroups and in the ITT population. *P < .05. Comparisons are presented as drug A versus drug B. Not all comparisons were possible at each blood eosinophil count threshold because of a lack of data from included studies. I2 values: 400 cells/μL or greater, 0% (MEPO vs PBO), NA (BENRA vs PBO), and 13% (RESLI vs PBO); 300 cells/μL or greater, 0% (MEPO vs PBO) and 0% (BENRA vs PBO); 150 cells/μL or greater, 0% (MEPO vs PBO) and NA (BENRA vs PBO); unadjusted comparison, 0% (MEPO vs PBO), 0% (BENRA vs PBO), and 13% (RESLI vs PBO). BENRA, Thirty milligrams of benralizumab Q8W; MEPO, 100 mg of mepolizumab administered subcutaneously; NA, not applicable; PBO, placebo; RESLI, 3 mg/kg reslizumab. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

7 Fig E1 Treatment comparison with placebo on the rate of clinically significant exacerbations in baseline blood eosinophil count subgroups and the ITT population. **P < .01 and ***P < .001. Comparisons are presented as drug versus placebo. Not all comparisons were possible at each blood eosinophil count threshold because of a lack of data from included studies. BENRA, Thirty milligrams of benralizumab Q8W; MEPO, 100 mg of mepolizumab administered subcutaneously; PBO, placebo; RESLI, 3 mg/kg reslizumab; SC, subcutaneous. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

8 Fig E2 Treatment comparison with placebo on the rate of exacerbations requiring ED visits/hospitalizations in baseline blood eosinophil count subgroups and the ITT population. *P < .05, **P < .01, and ***P = .001. Comparisons are presented as drug versus placebo. Not all comparisons were possible at each blood eosinophil count threshold because of a lack of data from included studies. BENRA, Thirty milligrams of benralizumab Q8W; MEPO, 100 mg of mepolizumab administered subcutaneously; PBO, placebo; RESLI, 3 mg/kg reslizumab; SC, subcutaneous. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

9 Fig E3 Treatment comparison with placebo on change from baseline in ACQ score in baseline blood eosinophil count subgroups and the ITT population. **P < .01 and ***P < .001. Comparisons are presented as drug versus placebo. Not all comparisons were possible at each blood eosinophil count threshold because of a lack of data from included studies. BENRA, Thirty milligrams of benralizumab Q8W; MEPO, 100 mg of mepolizumab administered subcutaneously; PBO, placebo; RESLI, 3 mg/kg reslizumab 3; SC, subcutaneous. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

10 Fig E4 Treatment comparison with placebo on change from baseline in prebronchodilator FEV1 (liters) in baseline blood eosinophil count subgroups and the ITT population. ***P < .001. Comparisons are presented as drug versus placebo. Not all comparisons were possible at each blood eosinophil count threshold because of a lack of data from included studies. BENRA, Thirty milligrams of benralizumab Q8W; MEPO, 100 mg of mepolizumab administered subcutaneously; PBO, placebo; RESLI, 3 mg/kg reslizumab; SC, subcutaneous. Journal of Allergy and Clinical Immunology  , e20DOI: ( /j.jaci ) Copyright © 2018 GlaxoSmithKline Terms and Conditions

Download ppt "Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,"

Similar presentations

Biologics in Asthma—The Next Step Toward Personalized Treatment

Biologics in Asthma—The Next Step Toward Personalized Treatment
The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity  Andrei Malinovschi,

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity  Andrei Malinovschi,
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD 

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD 
Pharmacologic rationale for treating allergic and nonallergic rhinitis

Pharmacologic rationale for treating allergic and nonallergic rhinitis
Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.
Asthma diagnosis and treatment: Filling in the information gaps

Asthma diagnosis and treatment: Filling in the information gaps
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.
Stanley J. Szefler, MD, Richard J. Martin, MD 

Stanley J. Szefler, MD, Richard J. Martin, MD 
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,
NAEPP Expert Panel Report

NAEPP Expert Panel Report

Similar presentations

Ads by Google